<SEC-DOCUMENT>0001558370-23-013237.txt : 20230803
<SEC-HEADER>0001558370-23-013237.hdr.sgml : 20230803
<ACCEPTANCE-DATETIME>20230803161610
ACCESSION NUMBER:		0001558370-23-013237
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230803
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230803
DATE AS OF CHANGE:		20230803

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NextCure, Inc.
		CENTRAL INDEX KEY:			0001661059
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				475231247
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38905
		FILM NUMBER:		231140260

	BUSINESS ADDRESS:	
		STREET 1:		9000 VIRGINIA MANOR ROAD, SUITE 200
		CITY:			BELTSVILLE
		STATE:			MD
		ZIP:			20705
		BUSINESS PHONE:		240-399-4900

	MAIL ADDRESS:	
		STREET 1:		9000 VIRGINIA MANOR ROAD, SUITE 200
		CITY:			BELTSVILLE
		STATE:			MD
		ZIP:			20705
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>nxtc-20230803x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.3.0.9 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 8/3/2023 6:14:15 PM -->
      <!-- iXBRL Library version: 1.0.8528.25195 -->
      <!-- iXBRL Service Job ID: 24be6a05-3134-4414-867d-84d9c1299879 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nxtc="http://nextcure.com/20230803" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg" name="dei:EntityCentralIndexKey" id="Tc_Kj8fmdzPcE-bDDM7046W5w_2_1">0001661059</ix:nonNumeric><ix:nonNumeric contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg" name="dei:AmendmentFlag" id="Tc_6r782ivFbkqamT5IOM26Og_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="nxtc-20230803.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-03</xbrli:startDate><xbrli:endDate>2023-08-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:746.95pt;"><div style="height:22.5pt;left:0%;position:absolute;top:724.45pt;width:468pt;z-index:251658240;"><div style="height:21.6pt;left:0pt;padding-bottom:0.9pt;position:relative;top:0pt;width:468pt;"><div style="height:21.6pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:468pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;padding-bottom:8pt;width:100%;margin:0pt;"><span style="font-size:7pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;border-bottom:1.0pt solid #000000;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><a id="_05756140_f937_43a5_819f_89c77a34915a"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:18pt;font-weight:bold;">UNITED STATES</b><b style="font-family:'Times New Roman','Times','serif';font-size:18pt;font-weight:bold;"><br /></b><b style="font-family:'Times New Roman','Times','serif';font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:18pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg" name="dei:DocumentType" id="Narr_1B3l5JccpECYt5J6UTOJ8Q"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">CURRENT REPORT</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"><br /></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Date of Report (Date of earliest event reported): </span><ix:nonNumeric contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_bC2cIL7LxUyqt26W-3ncVg"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">August 3, 2023</span></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:18pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg" name="dei:EntityRegistrantName" id="Narr_108do0hApUSBti3P_eh_NQ"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">NextCure, Inc.</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">(Exact name of registrant as specified in its charter)</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:31.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:31.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Narr_agrbvglHPk-6WEUj2R8fkw"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">Delaware</b></ix:nonNumeric><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;"><br /></b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">(State or other jurisdiction of incorporation)</span></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:top;width:31.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg" name="dei:EntityFileNumber" id="Narr_eO6X5ZstP0WkMjIBEfBKyw"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">001-38905</b></ix:nonNumeric><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;"><br /></b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">(Commission File Number)</span></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:top;width:31.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg" name="dei:EntityTaxIdentificationNumber" id="Narr_D8_ztPoOSEeeUcxEST6Aeg"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">47-5231247</b></ix:nonNumeric><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;"><br /></b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">(IRS Employer Identification No.)</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><a id="_2aff84aa_b833_42e6_86ca_720304bb3c4b"></a><a id="Tc_RzGcWqiirkGroc4oMpg0Zg_1_0"></a><a id="Tc_e-Y5ifxV3kqomgho__8B-w_2_0"></a><a id="Tc_bLwlY3-GqkSftub-3o2U7A_2_2"></a><a id="Tc__Jt2KRBpCkCgg3bhEAKJkQ_3_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg" name="dei:EntityAddressAddressLine1" id="Narr_wu3RD8M0C0uJKDkN8tzwww"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">9000 Virginia Manor Road</b></ix:nonNumeric><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg" name="dei:EntityAddressAddressLine2" id="Narr_TKoQPys7eE2QzF59lxp3zw"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">Suite 200</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg" name="dei:EntityAddressCityOrTown" id="Narr_IsO8R027o0ixtc2u5d-QaQ"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">Beltsville</b></ix:nonNumeric><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_zoOBe_O5akKZnd6H5hmOLA"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">Maryland</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg" name="dei:EntityAddressPostalZipCode" id="Tc__VeeaZAY_EiFlBIwQgHbdw_1_2"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">20705</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">(Address of principal</span></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p></td><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">(Zip Code)</span></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">executive offices)</span></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p></td><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Registrant&#39;s telephone number, including area code: </span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg" name="dei:CityAreaCode" id="Narr_Xaaw2YFhbkKukHSdLAZTqQ"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">240</b></ix:nonNumeric><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg" name="dei:LocalPhoneNumber" id="Narr_jK6wFdIjwUi8iRL54AHv2A"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">399-4900</b></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">(Former name or former address, if changed since last report.)</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_7sHcc38GuE-5UzJQyiSAEQ"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric><span style="font-family:'Wingdings';font-size:10pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_87VIpQIo_U-jErXFuP6cYQ"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric><span style="font-family:'Wingdings';font-size:10pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_Ro4gHYY0p0qTWPQgC8LMPw"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric><span style="font-family:'Wingdings';font-size:10pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_3tdJcdnOz0eDLmENz1MAJw"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric><span style="font-family:'Wingdings';font-size:10pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:10.7pt;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Securities registered pursuant to Section 12(b) of the Act:</span></p><a id="_6dbbe4be_96f8_4435_8798_5ad7ad542be8"></a><a id="Tc_3izCpR3A60OVQxsLfmO8ng_2_0"></a><a id="Tc_Y51p8zDHSkqzL_c5nyqLXQ_2_1"></a><a id="Tc_7V1CDuZtzEWmHnVnIs0KUw_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.76%;margin:0pt;padding:0pt 6.5pt 0pt 6.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:13.37%;margin:0pt;padding:0pt 6.5pt 0pt 6.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:37.86%;margin:0pt;padding:0pt 6.5pt 0pt 6.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:48.76%;margin:0pt;padding:0pt 6.5pt 0pt 6.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;min-height:0.0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p></td><td style="vertical-align:top;width:13.37%;margin:0pt;padding:0pt 6.5pt 0pt 6.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;min-height:0.0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p></td><td style="vertical-align:top;width:37.86%;margin:0pt;padding:0pt 6.5pt 0pt 6.5pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;min-height:0.0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p></td></tr><tr><td style="vertical-align:top;width:48.76%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 6pt 0pt 6pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;min-height:9.65pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:13.37%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 6pt 0pt 6pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;min-height:9.65pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:37.86%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 6pt 0pt 6pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;min-height:9.65pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:48.76%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 6pt 0pt 6pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;min-height:9.65pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg" name="dei:Security12bTitle" id="Tc_2wS-jq6rMEiJkRkcepy03Q_3_0"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;">Common Stock, $0.001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:13.37%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 6pt 0pt 6pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;min-height:9.65pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg" name="dei:TradingSymbol" id="Tc_sg4YN_1ArE24oruW-VxCYA_3_1"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;">NXTC</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:37.86%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 6pt 0pt 6pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;min-height:9.65pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_znOoRh8lS0yWgPZVPQKtSg_3_2"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;">Nasdaq Global Select Market</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:10.0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). Emerging growth company </span><ix:nonNumeric contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_3NRES957uECaByhcWze_4w"><span style="font-family:'Segoe UI Emoji';font-size:10pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-family:'Wingdings';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><ix:nonNumeric contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="Narr_YeFcj_zXb0ygK4htUdXjKQ"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;border-bottom:1.0pt solid #000000;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_90a1891b_e535_46b4_a775_9a408eedd2c8"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 2.02.</b></span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Results of Operations and Financial Condition.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">On August 3, 2023, NextCure, Inc. (the &#8220;Company&#8221;) issued a press release announcing its financial results for the quarter ended June 30, 2023. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">The information furnished in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, and is not incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><a id="_7af0846a_862f_42a7_bc2d_a5a4aaa18788"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 9.01.</b></span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Financial Statements and Exhibits</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">(d) Exhibits.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:9.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:88.03%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">No.</b></p></td><td style="vertical-align:top;width:2.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;width:9.08%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="nxtc-20230803xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">99.1</span></a></p></td><td style="vertical-align:top;width:2.88%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.03%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="nxtc-20230803xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press release issued by NextCure, Inc. dated August 3, 2023</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">104</p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.03%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Cover Page Interactive Data File (embedded within the inline XBRL document)</p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_80ad6676_3c51_40c3_a7e8_dbd242944b1b"></a><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">SIGNATURE</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">November</span></p></div></div></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:43.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Dated: August 3, 2023</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">NEXTCURE, INC.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p></td><td style="vertical-align:top;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;">By:          </span></p></td><td style="vertical-align:top;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;"> /s/ Steven P. Cobourn                  </span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Name:</span></p></td><td style="vertical-align:top;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Steven P. Cobourn</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;</span></p></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Title:</span></p></td><td style="vertical-align:top;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Chief Financial Officer </span></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>nxtc-20230803xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 8/3/2023 06:14:14 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><img src="nxtc-20230803xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:22.9pt;width:133.95pt;"></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:14pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:14pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8211;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;">Phase 1b data for NC410 and further updates on other clinical programs expected in the fourth quarter of 2023</i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8211;</td><td style="padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;">Cash of approximately $131 million expected to fund operations into mid-2025</i></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">BELTSVILLE, Md.</b><font style="font-size:12pt;"> </font><b style="font-size:12pt;font-weight:bold;">&#8211; August 3, 2023</b><font style="font-size:12pt;"> </font><b style="font-size:12pt;font-weight:bold;">&#8211;</b><font style="font-size:12pt;"> </font><u style="color:#0563c1;font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;">NextCure, Inc.</u><font style="font-size:12pt;"> (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases today provided a business update and reported second quarter 2023 financial results.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.25;margin:0pt;"><a name="_Hlk140659904"></a><font style="font-size:12pt;">&#8220;As we enter the remainder of 2023, we continue generating important data and are nearing updates on our clinical programs expected in the fourth quarter of this year,&#8221; said Michael Richman, NextCure&#8217;s president and chief executive officer. &#8220;We expect to continue to advance our programs while prudently managing our resources to support our financial runway into mid-2025.&#8221; </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.25;margin:0pt;"><font style="font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Q2 2023 Business Highlights and Near-Term Milestones</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.25;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">NC410 (LAIR-2 fusion)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.25;margin:0pt;"><font style="font-size:12pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">Continued enrollment in the Phase 1b/2 clinical trial evaluating NC410 in combination with pembrolizumab in patients with immune checkpoint naive or checkpoint refractory solid tumors.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">Phase 1b data are expected in the fourth quarter of 2023. </font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">NC762 (B7-H4 mAb)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">Continued enrollment in the Phase 1b dose expansion study in patients with solid tumors and high expression of B7-H4.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">Phase 1b update is expected in the fourth quarter of 2023. </font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">NC525 (LAIR-1 mAb)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">Continued enrollment in the Phase 1 monotherapy dose escalation and safety study evaluating NC525 in AML patients.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">Phase 1a update is expected in the fourth quarter of 2023.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">NC318 (Siglec-15)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">Yale Cancer Center to present in September, &#8220;NC318, an Anti-Siglec-15 Humanized mAb, Alone and in Combination with Pembrolizumab in Immunotherapy Pretreated NSCLC&#8221;, at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer in Singapore. </font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.25;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Financial Guidance</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.25;margin:0pt;"><font style="font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">NextCure&#160;expects its existing cash, cash equivalents and marketable securities will enable it to fund operating expenses and capital expenditures into mid-2025.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Financial Results for Quarter Ended June 30, 2023</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">Cash, cash equivalents, and marketable securities as of June 30, 2023, were $130.6 million as compared to $159.9 million as of December 31, 2022. The decrease of $29.3 million was primarily related to cash used to fund operations, and cash used to purchase fixed assets.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">Research and development expenses were $13.4 million for the quarter ended June 30, 2023, as compared to $12.8 million for the quarter ended June 30, 2022. The increase of $0.6 million was primarily related to higher clinical costs.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">General and administrative expenses were $5.7 million for the quarter ended June 30, 2023, as compared to $5.3 million for the quarter ended June 30, 2022. The increase of $0.4 million was primarily related to higher payroll and legal costs partially offset by lower stock compensation costs and lower insurance costs.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.25;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">Net loss was </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Hlk101268176"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">$17.9 million for the quarter ended June 30, 202</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">3, as compared with a net loss of $17.9 million for the quarter ended June 30, 2022. Higher research and development expenses and higher general and administrative expenses were offset by higher other income, primarily interest income.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">About NextCure, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;">NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines and other immune related-diseases to treat cancer. Through our proprietary FIND-IO&#8482; platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. </font><u style="color:#0563c1;font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;">www.nextcure.com</u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;background:#ffffff;margin:0pt;"><a name="_Hlk65678977"></a><font style="font-size:12pt;">Some of the statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to funding for </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;background:#ffffff;margin:0pt;"><font style="font-size:12pt;">our operations, objectives and expectations for our business, operations and financial performance and condition, including the progress and results of clinical trials, development plans and upcoming milestones regarding our immunomedicines. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;hope,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;positioned,&#8221; &#8220;seek,&#8221; &#8220;target,&#8221; &#8220;towards,&#8221; &#8220;forward,&#8221; &#8220;later,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or similar language.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;background:#ffffff;margin:0pt;"><font style="font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;background:#ffffff;margin:0pt;"><font style="font-size:12pt;">Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: positive results in preclinical studies may not be predictive of the results of clinical trials; NextCure&#8217;s limited operating history and not having any products approved for commercial sale; NextCure&#8217;s history of significant losses; NextCure&#8217;s need and ability to obtain additional financing on acceptable terms or at all; risks related to clinical development, marketing approval and commercialization; the unproven approach to the discovery and development of product candidates based on NextCure&#8217;s FIND-IO platform; and NextCure&#8217;s dependence on key personnel. More detailed information on these and additional factors that could affect NextCure&#8217;s actual results are described under the heading &#8220;Risk Factors&#8221; in NextCure&#8217;s most recent Annual Report on Form 10-K and in NextCure&#8217;s other filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this press release, and NextCure assumes no obligation to update any forward-looking statements, even if expectations change.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;background:#ffffff;margin:0pt;"><font style="font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:101.12%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td colspan="21" style="vertical-align:bottom;white-space:nowrap;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Selected Financial Information</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Selected Statement of Operations Items:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:24.41%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months Ended</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:26.23%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six&#160;Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:24.41%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:26.23%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">(in thousands, except share and per share amounts)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;</p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;</p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">Operating expenses: </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;margin:0pt;padding:0.75pt 0.75pt 0pt 9pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:10pt;margin:0pt;">Research and development</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0.75pt 0.75pt 0pt 9pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">13,447 </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">12,825 </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">25,094 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">27,849 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 9pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:10pt;margin:0pt;">General and administrative</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 9pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">5,711 </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">5,303 </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">11,135 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">11,050 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(19,158)</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(18,128)</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(36,229)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(38,899)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">Other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">1,299 </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">208 </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">2,274 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">377 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(17,859)</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:3px double transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(17,920)</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(33,955)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(38,522)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">Net loss per common share&#160;- basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(0.64)</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(0.65)</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(1.22)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(1.39)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">Weighted-average shares outstanding&#160;- basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">27,828,741 </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">27,744,762 </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">27,801,788 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">27,726,864 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Selected Balance Sheet Items:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">Cash, cash equivalents, and marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">130,623 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">159,911 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">153,380 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">184,161 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">7,820 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;background:#cceeff;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">9,127 </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.91%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">138,430 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0.75pt 0.75pt 0pt 0.75pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">167,530 </p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:6pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:82.35%;border-width:0;"><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Investor Inquiries</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;">Timothy Mayer, Ph.D.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;">NextCure, Inc.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;">Chief Operating Officer</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;">(240) 762-6486</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><u style="color:#0563c1;font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;">IR@nextcure.com</u></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:avoid;width:82.35%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>nxtc-20230803xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nxtc-20230803xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  N 0P# 2(  A$! Q$!_\0
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(O3E*?O/8_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>nxtc-20230803.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/3/2023 6:14:19 PM-->
<!--Modified on: 8/3/2023 6:14:19 PM-->
<xsd:schema targetNamespace="http://nextcure.com/20230803" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2022" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:nxtc="http://nextcure.com/20230803" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://nextcure.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="nxtc-20230803_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="nxtc-20230803_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="nxtc-20230803_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://nextcure.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>nxtc-20230803_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/3/2023 6:14:19 PM-->
<!--Modified on: 8/3/2023 6:14:19 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:roleRef roleURI="http://nextcure.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="nxtc-20230803.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:definitionLink xlink:role="http://nextcure.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>nxtc-20230803_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/3/2023 6:14:19 PM-->
<!--Modified on: 8/3/2023 6:14:19 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>nxtc-20230803_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/3/2023 6:14:19 PM-->
<!--Modified on: 8/3/2023 6:14:19 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="nxtc-20230803.xsd#DocumentDocumentAndEntityInformation" roleURI="http://nextcure.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://nextcure.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638266832592884584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638266832592884584" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638266832592884584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638266832592884584" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638266832592884584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638266832592884584" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638266832592884584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638266832592884584" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638266832592894586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638266832592894586" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638266832592894586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638266832592894586" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638266832592894586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638266832592894586" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638266832592894586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638266832592894586" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638266832592894586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638266832592894586" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638266832592894586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638266832592894586" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638266832592894586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638266832592894586" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638266832592894586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638266832592894586" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638266832592894586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638266832592894586" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638266832592894586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications_638266832592894586" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638266832592894586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial_638266832592894586" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638266832592894586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638266832592894586" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638266832592904556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638266832592904556" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638266832592904556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638266832592904556" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638266832592904556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638266832592904556" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638266832592904556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638266832592904556" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638266832592904556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638266832592904556" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_638266832592904556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_638266832592904556" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638266832592904556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638266832592904556" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638266832592904556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638266832592904556" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139855016034288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 03, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  03,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NextCure, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-5231247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9000 Virginia Manor Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Beltsville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">399-4900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NXTC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001661059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>nxtc-20230803x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nxtc-20230803.xsd" xlink:type="simple"/>
    <context id="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <startDate>2023-08-03</startDate>
            <endDate>2023-08-03</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg"
      id="Tc_Kj8fmdzPcE-bDDM7046W5w_2_1">0001661059</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg"
      id="Tc_6r782ivFbkqamT5IOM26Og_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg"
      id="Narr_1B3l5JccpECYt5J6UTOJ8Q">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg"
      id="Narr_bC2cIL7LxUyqt26W-3ncVg">2023-08-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg"
      id="Narr_108do0hApUSBti3P_eh_NQ">NextCure, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg"
      id="Narr_agrbvglHPk-6WEUj2R8fkw">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg"
      id="Narr_eO6X5ZstP0WkMjIBEfBKyw">001-38905</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg"
      id="Narr_D8_ztPoOSEeeUcxEST6Aeg">47-5231247</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg"
      id="Narr_wu3RD8M0C0uJKDkN8tzwww">9000 Virginia Manor Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg"
      id="Narr_TKoQPys7eE2QzF59lxp3zw">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg"
      id="Narr_IsO8R027o0ixtc2u5d-QaQ">Beltsville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg"
      id="Narr_zoOBe_O5akKZnd6H5hmOLA">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg"
      id="Tc__VeeaZAY_EiFlBIwQgHbdw_1_2">20705</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg"
      id="Narr_Xaaw2YFhbkKukHSdLAZTqQ">240</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg"
      id="Narr_jK6wFdIjwUi8iRL54AHv2A">399-4900</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg"
      id="Narr_7sHcc38GuE-5UzJQyiSAEQ">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg"
      id="Narr_87VIpQIo_U-jErXFuP6cYQ">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg"
      id="Narr_Ro4gHYY0p0qTWPQgC8LMPw">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg"
      id="Narr_3tdJcdnOz0eDLmENz1MAJw">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg"
      id="Tc_2wS-jq6rMEiJkRkcepy03Q_3_0">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg"
      id="Tc_sg4YN_1ArE24oruW-VxCYA_3_1">NXTC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg"
      id="Tc_znOoRh8lS0yWgPZVPQKtSg_3_2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg"
      id="Narr_3NRES957uECaByhcWze_4w">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg"
      id="Narr_YeFcj_zXb0ygK4htUdXjKQ">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M4$L! A0#%     @ !((#5QKF+L;N    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ !((#5YE<G",0!@  G"<
M !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    "  $@@-7)X(@JX,$  #H$0  &               @($-"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ !((#5Y^@&_"Q @  X@P
M  T              ( !Q@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  $
M@@-7EXJ[',     3 @  "P              @ &B#P  7W)E;',O+G)E;'-0
M2P$"% ,4    "  $@@-7'#AEZC\!   \ @  #P              @ &+$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ !((#5R0>FZ*M    ^ $  !H
M             ( !]Q$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ !((#5V60>9(9 0  SP,  !,              ( !W!(  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  )A0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="nxtc-20230803x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nextcure.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="nxtc-20230803x8k.htm">nxtc-20230803x8k.htm</File>
    <File>nxtc-20230803.xsd</File>
    <File>nxtc-20230803_def.xml</File>
    <File>nxtc-20230803_lab.xml</File>
    <File>nxtc-20230803_pre.xml</File>
    <File>nxtc-20230803xex99d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nxtc-20230803x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 24
   },
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "nxtc-20230803_def.xml"
     ]
    },
    "inline": {
     "local": [
      "nxtc-20230803x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nxtc-20230803_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nxtc-20230803_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nxtc-20230803.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "nxtc",
   "nsuri": "http://nextcure.com/20230803",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20230803x8k.htm",
      "contextRef": "Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://nextcure.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20230803x8k.htm",
      "contextRef": "Duration_8_3_2023_To_8_3_2023_J0ZToPwZOUWaUGh1xND_Fg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Adress Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001558370-23-013237-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-013237-xbrl.zip
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MO,C.=V/\R^),![R"M?SV?)L3K^:S&1_5P0SZVY\,\M]V0LMY_1U02P,$%
M  @ !((#5XK(4\?J @  - L  !4   !N>'1C+3(P,C,P.# S7V1E9BYX;6S%
M5EUOVR 4?9^T_\#<9XR=;%-C-:W:YF52HDWM)O6M(O9U@HK! KQD_WZ /^HT
M:9MUGO9B&[B<>\XQ'_?L8EMP]!.49E),@SB, @0BE1D3JVE0:4QUREAP<?[^
MW=D'C.^N;N8HDVE5@# H54 -9&C#S!I]EV5)!5J 4HQS=*58M@*$XB@<AU$X
M01@W&%=4VSE2( \V"N-NY+K!DR)!IV1,1M%HC#XG\<<DGJ!OBRYN8>GE[+5
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MU<8-I-TN2E?NMN=[<23_P4K^4G[VS7]02P,$%     @ !((#5U1+OF:I!
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MA4/)RISH>J]4O/4S)]FK1N5$N5SH%!7N-&2[:4]FPX9OKOC%V9H2]&2M=-%
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M'U!+ 0(4 Q0    (  2" U?;"J&2U0,  &0/   1              "  0
M  !N>'1C+3(P,C,P.# S+GAS9%!+ 0(4 Q0    (  2" U>*R%/'Z@(  #0+
M   5              "  00$  !N>'1C+3(P,C,P.# S7V1E9BYX;6Q02P$"
M% ,4    "  $@@-73<3H#?(%  !+1@  %0              @ $A!P  ;GAT
M8RTR,#(S,#@P,U]L86(N>&UL4$L! A0#%     @ !((#5U1+OF:I!   8BX
M !4              ( !1@T  &YX=&,M,C R,S X,#-?<')E+GAM;%!+ 0(4
M Q0    (  2" U<L;L2LW!4  "NX   4              "  2(2  !N>'1C
M+3(P,C,P.# S>#AK+FAT;5!+ 0(4 Q0    (  2" U>++0'32Q@  '<U 0 8
M              "  3 H  !N>'1C+3(P,C,P.# S>&5X.3ED,2YH=&U02P4&
2      8 !@"0 0  L4

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
